Page last updated: 2024-10-17
octanoic acid and Antibody Deficiency Syndrome
octanoic acid has been researched along with Antibody Deficiency Syndrome in 1 studies
octanoic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #1764
octanoic acid : A straight-chain saturated fatty acid that is heptane in which one of the hydrogens of a terminal methyl group has been replaced by a carboxy group. Octanoic acid is also known as caprylic acid.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " Pharmacokinetic parameters were determined after the third infusion of each product." | 2.71 | Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ( Ballow, M; Berger, M; Bonilla, FA; Buckley, RH; Cunningham-Rundles, CH; Fireman, P; Kaliner, M; Lathia, C; Ochs, HD; Skoda-Smith, S; Sweetser, MT; Taki, H, 2003) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Ballow, M | 1 |
| Berger, M | 1 |
| Bonilla, FA | 1 |
| Buckley, RH | 1 |
| Cunningham-Rundles, CH | 1 |
| Fireman, P | 1 |
| Kaliner, M | 1 |
| Ochs, HD | 1 |
| Skoda-Smith, S | 1 |
| Sweetser, MT | 1 |
| Taki, H | 1 |
| Lathia, C | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)[NCT01281969] | Phase 3 | 48 participants (Actual) | Interventional | 2011-01-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Children's Yale-Brown Obsessive Compulsive Scale Total Score
Active IVIG will be significantly superior to sham IVIG in reducing OC symptoms and providing global relief of neuropsychiatric symptomatology. Total score is reported as the sum of all items and has a range of 0-40. Higher scores indicate more severe symptoms. (NCT01281969)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|
| Group A | 20.59 |
| Group B | 25.67 |
Clinical Global Impressions Improvement
1=very much improved, 2=much improved, 3=slightly improved, 4=no change, 5=slightly worse, 6=much worse, 7=very much worse (NCT01281969)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|
| Group A | 2.88 |
| Group B | 3.53 |
Clinical Responder to Treatment
"Defined as a CGI-I score of 1 or 2 (much or very much improved) and a decrease in CY-BOCS of at least 30%" (NCT01281969)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|
| Group A | 6 |
| Group B | 4 |
The Degree of Treatment Response is Expected to Correlate With the Percentage Reduction in Antinuclear Antibody Titers Following IVIG Administration.
"Non-zero values of antinuclear antibodies are considered positive and reflective of an ongoing immune response in the individual. First, the number of participants who were classified at baseline as having positive antinuclear antibodies was calculated (see outcome measure data table, which states the number (AKA count) of participants who had positive antinuclear antibodies at baseline). We hypothesized that improvement in the ongoing immune response, and therefore a reduction in antinuclear antibody titers, would mediate the effect of IVIG on OCD symptom improvement. However, because very few participants were classified as positive at baseline, it was not appropriate to pursue the original question of whether a decline in antinuclear antibodies (i.e., from positive to negative) was related to symptom improvement." (NCT01281969)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|
| IVIG | 8 |
| Placebo | 5 |
Trials
1 trial available for octanoic acid and Antibody Deficiency Syndrome